Insys Therapeutics (INSY) reached an agreement in principle with the Department of Justice to pay $150 million over the next five years to settle civil and criminal investigations into allegedly illegal marketing of its fentanyl opioid by some of its former employees. The company could pay up to another $75 million, depending upon other undisclosed conditions.

The deal comes amid long-running probes by federal and state authorities into the abuse and misuse of opioid painkillers, and the extent to which they are appropriately prescribed. Insys has figured prominently in this drama, as several former executives and employees have been arrested in connection with allegations of bribing doctors to boost sales of Subsys, which contains fentanyl, a highly addictive opioid.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy